Ravindran Research Lab - Biomarkers

Ravindran Research Lab

About us | Physicians | Patients | Refer

Clinical Trials

Esketamine acute treatment

Diagnosis: MDD

Study: Efficacy and tolerability of esketamine, a novel ‘standard of care’ treatment, for the management of patients with treatment-resistant depression: An observational study (4 week, open-label)

This is a multicenter observational study designed to assess the efficacy and tolerability of flexibly dosed intranasal esketamine for subjects with treatment resistant depression.

Inclusion:

18-65 years old
Health Canada approval to add esketamine treatment to standard of care

Exclusion

Exclusion criteria will be addressed by the requirement for approval

Unfavourable benefit vs risk ratio
Neurodegenerative disorder, cognitive impairment, or intellectual disability
Clinically significant uncontrolled hypertension or other cardiovascular conditions
Sleep apnea in those with BMI greater than 35
Urinary conditions
Previous major head trauma
Previous diagnosis of substance use disorder or significant history of use in past two years
Significant cluster of personality traits / disorder or suicidal behaviour
Pregnant, breastfeeding, or planning to become pregnant during study or within 6 weeks of last dose of study drug
Any condition or circumstance which would indicate participation may not be in participant’s best interest